AC Immune SA: insider trades · United States · SEC (Form 4)

About AC Immune SA

AC Immune SA is a clinical-stage biotechnology company focused on neurodegenerative diseases. It is listed on the NASDAQ market in the United States under the ticker ACIU, while its operational base and corporate headquarters are in Lausanne, Switzerland, at the EPFL Innovation Park. Founded in 2003, the company has built its identity around precision medicine approaches for disorders driven by misfolded proteins, with core focus areas including Alzheimer’s disease, Parkinson’s disease, and selected NeuroOrphan indications. For investors, this is a classic high-risk/high-upside biotech profile: valuation is typically driven by clinical readouts, safety and biomarker data, partnership economics, and balance-sheet visibility. AC Immune’s business is organized around a differentiated neuroscience pipeline and proprietary technology platforms. The company has developed expertise in targeting key pathological proteins such as tau, alpha-synuclein, amyloid beta, and other misfolded protein species implicated in neurodegeneration. Its portfolio includes active immunotherapies, small-molecule programs, and diagnostic or biomarker-related assets. That combination gives AC Immune exposure to both treatment and early intervention strategies, as well as the possibility of patient stratification through biomarker tools. From an investment standpoint, the company’s scientific platform is important because it can support multiple shots on goal, but the business remains highly dependent on clinical execution. In competitive terms, AC Immune operates in one of the most challenging and closely watched areas of biotech. It competes indirectly with large pharmaceutical companies and specialist neuroscience developers pursuing Alzheimer’s and Parkinson’s therapies. Its differentiation lies in platform science, especially active immunotherapy, precision prevention, and the ability to develop both therapeutic and diagnostic solutions around disease biology. Recent milestones have been meaningful: in 2025 and 2026 the company reported positive interim Phase 2 data for ACI-7104.056 in Parkinson’s disease, published peer-reviewed Phase 1b/2a results for ACI-35.030/JNJ-2056 in Alzheimer’s disease, advanced ACI-24.060, and initiated studies to support an IND filing for ACI-19764, a novel NLRP3 inhibitor. Management also sharpened pipeline focus to concentrate resources on the most strategic assets and indicated cash runway to the end of Q3 2027 before potential milestone receipts. Overall, AC Immune SA is a Switzerland-based neuroscience biotech with a U.S. NASDAQ listing, a concentrated but scientifically sophisticated pipeline, and a catalyst-rich profile that should be evaluated primarily through the lens of upcoming clinical data and partnership progress.